Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 18575 Jamboree Road, Suite 275-S IRVINE CA 92612 |
Tel: | N/A |
Website: | https://reneopharma.com |
IR: | See website |
Key People | ||
Michael Grey Executive Chairman of the Board | Gregory J. Flesher President, Chief Executive Officer, Director | Michael P. Cruse Chief Operating Officer |
Alejandro Dorenbaum Chief Medical Officer | Ashley F. Hall Chief Development Officer |
Business Overview |
Reneo Pharmaceuticals, Inc. is a pharmaceutical company. The Company is focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP). The Company's product candidate, mavodelpar, is a potent and selective agonist of the peroxisome proliferator-activated receptor delta (PPARd). Mavodelpar helps in increasing the transcription of genes involved in mitochondrial function and increases fatty acid oxidation (FAO) and may increase the production of new mitochondria. The Company is developing REN001 in the two rare genetic diseases that present with myopathy and have unmet medical needs: primary mitochondrial myopathies (PMM), and long-chain fatty acid oxidation disorders (LC-FAOD). |
Financial Overview |
For the three months ended 31 March 2024, Reneo Pharmaceuticals Inc revenues was not reported. Net loss decreased 44% to $8.4M. Lower net loss reflects Research and development - Balancing val decrease of 55% to $4.7M (expense), General and administrative - Balancing v decrease of 15% to $3.8M (expense), Stock-based Compensation in R&D decrease of 47% to $253K (expense). |
Employees: | 8 as of Mar 31, 2024 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | N/A |
Annual revenue (TTM): | $0.00M as of Mar 31, 2024 |
EBITDA (TTM): | -$76.35M as of Mar 31, 2024 |
Net annual income (TTM): | -$70.71M as of Mar 31, 2024 |
Free cash flow (TTM): | -$75.70M as of Mar 31, 2024 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 33,420,808 as of May 3, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |